GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report)’s stock price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $25.42 and traded as low as $22.73. GENMAB A/S/S shares last traded at $23.12, with a volume of 2,491,240 shares changing hands.
GENMAB A/S/S Trading Up 1.3 %
The business has a fifty day moving average price of $25.42 and a 200 day moving average price of $26.91.
About GENMAB A/S/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Articles
- Five stocks we like better than GENMAB A/S/S
- What to Know About Investing in Penny Stocks
- Texas Roadhouse Stock Steering for New Highs This Year
- What is the S&P/TSX Index?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Find Undervalued Stocks
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.